Clinical Trial Update: Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid

View source ↗

Summary

Dupilumab has been approved for marketing to treat Bullous Pemphigoid in adults. This expands its approved indications to an autoimmune blistering disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bullous Pemphigoid

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Bullous Pemphigoid | Status: APPROVED_FOR_MARKETING